Germany-based Stratec Biomedical has an option to acquire up to 7% of US-based healthcare testing peer Quanterix as part of a partnership. The two companies said they would co–develop and manufacture a fully–automated instrument for Quanterix’s SiMoA technology (pictured) for use in both the life sciences and in vitro diagnostics (IVD) markets. As part of the agreement, Quanterix will receive access to Stratec’s platform technology, in return for payments and a minority stake of 7% depending on upon technological milestones being hit. Founded in 2007, Quanterix is backed by venture capital firms Arch Venture Partners, Bain Capital Ventures, and Flagship Ventures.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?